Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers

Journal of Clinical Pharmacology
Wen-Lin LuoEseng Lai

Abstract

Laropiprant (LRPT), a prostaglandin D(2) receptor-1 antagonist shown to reduce niacin-induced flushing symptoms, has been combined with niacin for treatment of dyslipidemia. This study evaluated the effects of LRPT (50 mg and 600 mg, respectively) on the QT interval with Fridericia's correction (QTcF). QTcF measurements were made over a 24-hour period following administration of single-dose moxifloxacin 400 mg, LRPT 50 mg, LRPT 600 mg, or placebo. The primary hypothesis was supported if the 90% confidence intervals (CIs) for the least squares (LS) mean differences between placebo and LRPT in change from baseline in QTcF interval were <10 milliseconds at every time point. The upper limits of the 90% CIs for LS mean differences from placebo in changes from baseline in QTcF intervals for LRPT 50 mg and 600 mg were <5 milliseconds at every time point. The lower limits of the 90% CIs for placebo-adjusted LS mean changes from baseline in QTcF intervals for moxifloxacin exceeded 0 milliseconds at every time point, demonstrating the sensitivity of this assay to detect increases in the QTcF interval. In conclusion, single doses of LRPT 50 mg and 600 mg do not prolong the QTcF interval relative to placebo and are generally well tolerated.

References

Sep 1, 1985·Clinical Pharmacology and Therapeutics·J K WilkinW C Streeter
Apr 4, 1981·Lancet·W S Phillips, S L Lightman
Dec 21, 2000·Current Atherosclerosis Reports·D M CapuzziC M Intenzo
Nov 15, 2003·BMC Clinical Pharmacology·Edward MillsDavid Juurlink
Jul 16, 2005·Journal of Internal Medicine·L A Carlson
Apr 18, 2006·Proceedings of the National Academy of Sciences of the United States of America·Kang ChengM Gerard Waters
Sep 30, 2006·Molecular Pharmacology·Zoltán BenyóStefan Offermanns
Sep 30, 2006·The Journal of Investigative Dermatology·Dominique Maciejewski-LenoirDaniel T Connolly
Apr 14, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bindhu KaranamEseng Lai
Sep 21, 2007·Clinical Pharmacology and Therapeutics·E LaiJ A Wagner
Mar 1, 2008·The American Journal of Cardiology·John F PaoliniChristie M Ballantyne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.